Follistatin vs Orforglipron
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
Follistatin
Follistatin is a glycoprotein that inhibits myostatin, the protein responsible for limiting muscle growth. By blocking myostatin, follistatin can theoretically allow for increased muscle development beyond natural limits.
Full details →Orforglipron
Orforglipron (LY3502970) is a non-peptide, oral GLP-1 receptor agonist developed by Eli Lilly. Unlike oral semaglutide (which is a peptide requiring special formulation), orforglipron is a small molecule — the first of a new class of oral GLP-1 drugs that can be taken without fasting restrictions. It is in Phase 3 trials for obesity and type 2 diabetes, with an FDA decision expected in 2026. Projected to reach $16 billion in annual sales by 2031.
Full details →Side-by-Side Comparison
| Aspect | Follistatin | Orforglipron |
|---|---|---|
| Dose Range | 50 mcg–100 mcg | 12 mg–45 mg |
| Frequency | 1x daily | 1x daily |
| Cycle Length | 2–4 weeks | — |
| Route | subcutaneous | oral |
| Mechanism | Binds to and neutralizes myostatin and activin, both of which are negative regulators of muscle mass. This removes the natural brake on muscle growth, allowing for enhanced hypertrophy. | Orforglipron is a small-molecule agonist that binds and activates the GLP-1 receptor through the same signaling cascade as peptide GLP-1 agonists (cAMP elevation, insulin secretion, appetite suppression) but with a fundamentally different molecular structure. Being a non-peptide, it does not require protection from enzymatic degradation (no fatty acid conjugation needed), can be absorbed without special formulation, and has no fasting restrictions for administration. Once-daily oral dosing with a half-life of ~25-65 hours. |
| Typical Dosage | Research protocols typically use 100-300mcg daily, though optimal dosing is not well established. Gene therapy approaches have also been studied. | Phase 2 trial doses: 12 mg, 24 mg, 36 mg, and 45 mg daily. The 36 mg and 45 mg doses showed greatest efficacy. Phase 3 trials are evaluating doses of 12-60 mg daily. No fasting requirement — can be taken with or without food at any time of day. Final approved dosing not yet established. |
| Administration | Subcutaneous injection. Different isoforms exist (FS344, FS315) with varying properties. Requires careful sourcing due to complexity. | Oral tablet, once daily. No fasting restrictions required (a major advantage over oral semaglutide). Phase 3 trials ongoing. Expected FDA decision in 2026. Not yet commercially available. |
| Side Effects | Limited human data. Theoretical concerns about effects on other organs where activin signaling is important. | Phase 2 data: nausea (up to 35%), vomiting (up to 19%), diarrhea (up to 18%), constipation, decreased appetite. GI side effects were dose-dependent and generally transient, decreasing with continued use. Discontinuation rates due to GI events were 6-12%. |
| Best For |
Key Differences
Unique to Follistatin:
Unique to Orforglipron:
Key Studies
Follistatin
- Heart to Heal: Unveiling Follistatin's Potential for Myocardial Regeneration.
Circulation research, 2025
- Fructose and follistatin potentiate acute MASLD during complete hepatic insulin resistance.
Nature communications, 2025
- Follistatin drives neuropathic pain in mice through IGF1R signaling in nociceptive neurons.
Science translational medicine, 2024
Orforglipron
- Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3): a multinational, multicentre, non-inferiority, open-label, randomised, phase 3 trial.
Lancet (London, England), 2026
- Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial.
Nature medicine, 2026
- Orforglipron Added to Titrated Insulin Glargine in Type 2 Diabetes: The ACHIEVE-5 Randomized Clinical Trial.
JAMA, 2026
Ready to Learn More?
Looking for trusted sources?